News|Articles|October 16, 2023

PacBio Adds David Meline to Board of Directors

Executive previously served as chief financial officer of Moderna, Amgen, and 3M.

PacBio, a developer of sequencing solutions, announced the appointment of David Meline to its board of directors. Before joining PacBio, Meline most recently worked as chief financial officer of Moderna. Before joining Moderna, he spent time in the same role for both Amgen and 3M between 2008 and 2020.

"I am thrilled to join the PacBio Board at this pivotal stage," said Meline. "I've dedicated the latter part of my career to leading healthcare organizations that leveraged the power of genomics to develop some of the most groundbreaking therapies, so naturally, PacBio's mission resonated with me. I believe the industry has only scratched the surface on how genomics can transform human health and am eager to help guide the company as it executes this mission."

Reference: PacBio Announces Appointment of David Meline to Board of Directors. PR Newswire. October 16, 2023. Accessed October 16, 2023. https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.